Search results
Ligand (LGND) to Post Q2 Earnings: What's in Store?
Zacks via Yahoo Finance· 11 months agoLigand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs...
Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 1 year agoAmgen AMGN reported first-quarter 2023 earnings of $3.98 per share, which beat the Zacks Consensus...
Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio
Zacks via Yahoo Finance· 1 year agoLigand's (LGND) proprietary platforms enable it to form partnerships with several leading drug...
20 Countries with Lowest Rates of Cancer
Insider Monkey via Yahoo Finance· 8 months agoIn this article, we will be taking a look at the 20 countries with lowest rates of cancer. If you want to skip our analysis of the oncology industry,...
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoVolume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to...
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Zacks via Yahoo Finance· 2 months agoLigand Pharmaceuticals Incorporated LGND reported core adjusted diluted net income per share of...
Amgen (AMGN) Valuation: A Comprehensive Analysis of Its Market Value
GuruFocus.com via Yahoo Finance· 9 months agoAs of October 10, 2023, Amgen Inc (NASDAQ:AMGN) experienced a day's loss of -1.02%, with a 3-month...
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
Zacks via Yahoo Finance· 2 years agoAmgen AMGN reported second-quarter 2022 earnings of $4.65 per share, which beat the Zacks Consensus...
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
Zacks via Yahoo Finance· 2 years agoLigand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on...
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
Zacks via Yahoo Finance· 1 year agoShares of Ligand Pharmaceuticals Incorporated LGND rose 3.4% on Friday in response to the company’s...